Free Content

The difference between effectiveness and efficacy of antimalarial drugs in Kenya

Authors: Amin, Abdinasir A.1; Hughes, Dyfrig A.2; Marsh, Vicki; Abuya, Timothy O.3; Kokwaro, Gilbert O.1; Winstanley, Peter A.2; Ochola, Sam A.4; Snow, Robert W.

Source: Tropical Medicine & International Health, Volume 9, Number 9, September 2004 , pp. 967-974(8)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Objective 

To demonstrate the difference between effectiveness and efficacy of antimalarial (AM) drugs in Kenya. Methods 

We undertook a series of linked surveys in four districts of Kenya between 2001 and 2002 on (i) community usage of nationally recommended first- and second-line AM drugs; (ii) commonly stocked AM products in the retail and wholesale sectors; and (iii) quality of the most commonly available first- and second-line AM products. These were combined with estimates of adherence and clinical efficacy to derive overall drug effectiveness. Results 

The overall modelled effectiveness for sulphadoxine–pyrimethamine (SP) was estimated to be 62% compared with 85% for reported SP clinical efficacy. For amodiaquine the modelled effectiveness was 48% compared with 99% reported efficacy during the same time period. Conclusions 

The quality of AM products and patient adherence to dosage regimens are important determinants of drug effectiveness, and should be measured alongside clinical efficacy. Post-registration measures to regulate drug quality and improve patient adherence would contribute significantly to AM drug performance.

Keywords: Kenya; adherence; antimalarial drugs; effectiveness; efficacy; quality

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1365-3156.2004.01291.x

Affiliations: 1:  Kenya Medical Research Institute/Wellcome Trust Collaborative Programme, Nairobi, Kenya 2:  Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK 3:  Kenya Medical Research Institute/Centre for Geographic Medicine Coast Research, Kilifi, Kenya 4:  Division of Malaria Control, Ministry of Health, Nairobi, Kenya

Publication date: September 1, 2004

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page